MA37753B1 - Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée - Google Patents

Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée

Info

Publication number
MA37753B1
MA37753B1 MA37753A MA37753A MA37753B1 MA 37753 B1 MA37753 B1 MA 37753B1 MA 37753 A MA37753 A MA 37753A MA 37753 A MA37753 A MA 37753A MA 37753 B1 MA37753 B1 MA 37753B1
Authority
MA
Morocco
Prior art keywords
ylethyl
benzothiazol
pyridazin
sulfanyl
triazolo
Prior art date
Application number
MA37753A
Other languages
English (en)
Other versions
MA37753A3 (fr
MA37753A2 (fr
Inventor
Jean-René Authelin
Sylvie Assadourian
Tsiala Benard
Hélène Goulaouic
Amandine Mathieu
Maria-Teresa Peracchia
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA37753A2 publication Critical patent/MA37753A2/fr
Publication of MA37753A3 publication Critical patent/MA37753A3/fr
Publication of MA37753B1 publication Critical patent/MA37753B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée et son utilisation dans le traitement du cancer.
MA37753A 2012-07-12 2013-07-11 Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée MA37753B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305840 2012-07-12
PCT/EP2013/064741 WO2014009500A1 (fr) 2012-07-12 2013-07-11 Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée

Publications (3)

Publication Number Publication Date
MA37753A2 MA37753A2 (fr) 2016-06-30
MA37753A3 MA37753A3 (fr) 2018-05-31
MA37753B1 true MA37753B1 (fr) 2019-04-30

Family

ID=48782350

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37753A MA37753B1 (fr) 2012-07-12 2013-07-11 Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée

Country Status (25)

Country Link
US (1) US20150119391A1 (fr)
EP (1) EP2872119A1 (fr)
JP (1) JP2015525754A (fr)
KR (1) KR20150030761A (fr)
CN (1) CN104470500A (fr)
AR (1) AR091727A1 (fr)
AU (1) AU2013288676A1 (fr)
BR (1) BR112015000497A2 (fr)
CA (1) CA2878500A1 (fr)
CL (1) CL2015000074A1 (fr)
CO (1) CO7160069A2 (fr)
CR (1) CR20150005A (fr)
EA (1) EA201590199A1 (fr)
HK (1) HK1209642A1 (fr)
IL (1) IL236662A0 (fr)
IN (1) IN2015KN00075A (fr)
MA (1) MA37753B1 (fr)
MX (1) MX2015000532A (fr)
PH (1) PH12015500060A1 (fr)
SG (1) SG11201500123XA (fr)
TN (1) TN2015000011A1 (fr)
TW (1) TW201402121A (fr)
UY (1) UY34909A (fr)
WO (1) WO2014009500A1 (fr)
ZA (1) ZA201500129B (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
NZ541658A (en) * 2003-01-14 2008-04-30 Teva Pharma Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
BRPI0908077A2 (pt) * 2008-02-28 2015-08-25 Takeda Pharmaceutical Composição farmacêutica, métodos para prevenir ou tratar doenças, e para melhorar solubilidade em água de um composto, um sal ou uma pró-droga do mesmo
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Also Published As

Publication number Publication date
TN2015000011A1 (en) 2016-06-29
ZA201500129B (en) 2015-12-23
IL236662A0 (en) 2015-02-26
JP2015525754A (ja) 2015-09-07
CR20150005A (es) 2015-04-06
EP2872119A1 (fr) 2015-05-20
CL2015000074A1 (es) 2015-06-12
US20150119391A1 (en) 2015-04-30
WO2014009500A1 (fr) 2014-01-16
PH12015500060A1 (en) 2015-03-02
UY34909A (es) 2013-11-29
MA37753A3 (fr) 2018-05-31
MA37753A2 (fr) 2016-06-30
CO7160069A2 (es) 2015-01-15
TW201402121A (zh) 2014-01-16
BR112015000497A2 (pt) 2017-06-27
AR091727A1 (es) 2015-02-25
SG11201500123XA (en) 2015-02-27
KR20150030761A (ko) 2015-03-20
EA201590199A1 (ru) 2015-05-29
AU2013288676A1 (en) 2015-02-05
HK1209642A1 (en) 2016-04-08
MX2015000532A (es) 2015-05-15
CN104470500A (zh) 2015-03-25
CA2878500A1 (fr) 2014-01-16
IN2015KN00075A (fr) 2015-07-31

Similar Documents

Publication Publication Date Title
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
TR201911244T4 (tr) İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı.
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MX2019010709A (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
PH12015502549A1 (en) Heterocyclic derivatives
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
WO2015009726A3 (fr) Utilisations médicales d'agonistes de cd38
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
CL2016000150A1 (es) Compuestos y composiciones como inhibidores de la mek
EA201591379A1 (ru) Липопротеин-ассоциированные ингибиторы фосфолипазы a2 (lp-pla) на основе 2,3-дигидроимидазо[1,2-с]пиримидин-5(1h)-онов
CY1116186T1 (el) Μακροκυκλικες ενωσεις και μεθοδοι για την παραγωγη τους
EA201790259A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
EA201201483A1 (ru) Способы и композиции для защиты от нейротоксических веществ
SA515370253B1 (ar) مركب أميد عطري غير متجانس الحلقة يحتوي على نتروجين ثنائي الحلقة
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
MA37753A3 (fr) Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée
RU2013107122A (ru) 6-ЗАМЕЩЕННЫЕ 3-АЗОЛИЛИМИДАЗО[1,2-b][1,2,4,5]ТЕТРАЗИНЫ, ПРОЯВЛЯЮЩИЕ ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ
BR112015013196A2 (pt) combinações de um composto inibidor de pi3k/akt com um composto inibidor de her3/egfr e métodos de uso
MA34380B1 (fr) Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine
UA79303U (ru) Применение таурина как средства стабилизации концентрации итраконазола в плазме крови при лечении грибковых заболеваний
NZ629459A (en) Methods for treating cancer using tor kinase inhibitor combination therapy